文献速递眼底病与葡萄膜炎

BEVORDEX试验五年结果:地塞米松植入剂与贝伐珠单抗治疗糖尿病黄斑水肿的长期疗效与安全性

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.
PubMed 文献 · Br J Ophthalmol · 2021-08-02

BEVORDEX试验将糖尿病黄斑水肿眼随机分配接受玻璃体内地塞米松植入剂或贝伐珠单抗治疗2年,5年随访显示两组视力增益普遍丧失但黄斑厚度无变化,初始地塞米松组治疗次数更少但进展为增殖性糖尿病视网膜病变的比例更高,两组白内障手术比例相似。

要点

  • 5年时两组视力增益普遍丧失,但黄斑厚度自试验结束至5年无变化。
  • 初始地塞米松植入剂组治疗次数显著更少,但5年内进展为增殖性糖尿病视网膜病变的比例更高。
  • 两组5年内行白内障手术的比例相似。

核心结论

  • 初始接受地塞米松植入剂或贝伐珠单抗治疗2年后按标准临床护理,5年视力和解剖结局相似,但地塞米松组进展为增殖性糖尿病视网膜病变更多。

研究设计与样本

  • BEVORDEX试验的5年随访研究,患者完成2年随机试验后接受标准临床护理,回顾病历评估视觉和解剖结局、试验后治疗及并发症。
  • 5年数据可获取于59%的入组眼,3年数据可获取于82%的入组眼。

主要发现

  • 两组试验结束时视力增益至5年时普遍丧失,但黄斑厚度自试验结束至5年无变化。
  • 两组5年时从入组起视力增益≥10字母的眼比例相似。
  • 初始地塞米松植入剂组治疗次数显著更少,但5年内进展为增殖性糖尿病视网膜病变的可能性更高。
  • 两组5年内行白内障手术的眼比例相似。

临床怎么用

  • 对于糖尿病黄斑水肿,初始地塞米松植入剂或贝伐珠单抗治疗2年后按标准护理,5年视力和解剖结局相似。
  • 初始地塞米松植入剂治疗者需关注增殖性糖尿病视网膜病变的发生风险。

局限性

  • 5年数据仅可获取于59%的入组眼,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment. METHODS: Patients received standard clinical care after they finished the study. Their files were reviewed for visual and anatomical outcomes, post-trial treatments and complications. RESULTS: Three-year and five-year data were available for 82% and 59% of eyes enrolled in the BEVORDEX study, respectively. Visual acuity gains at end of trial were generally lost by both treatment groups at 5 years but the macular thickness did not change from end of trial to 5 years. A similar proportion of eyes from each treatment group gained ≥10 letters at 5 years from enrolment in the BEVORDEX trial.Eyes that were initially randomised to the DEX-implant group had significantly fewer treatments but were more likely to develop proliferative diabetic retinopathy (PDR) over the 5-year period compared with eyes initially randomised to bevacizumab. The proportion of eyes that had cataract surgery by 5 years was similar between initial treatment groups. CONCLUSIONS: Eyes in the BEVORDEX trial had similar 5-year rates of cataract surgery, however, more eyes converted to PDR in the group initially treated with DEX-implant. Eyes that were initially treated for 2 years with either intravitreal DEX-implant of bevacizumab followed by standard of care had similar visual and anatomical outcomes at 5 years.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Cornish EE, Teo KY, Gillies MC, et al. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. Br J Ophthalmol. 2021. PMID: 34340975. doi:10.1136/bjophthalmol-2021-319839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。